JonesTrading analyst Soumit Roy has reiterated their bullish stance on JANX stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy has given his Buy rating due to a combination of factors surrounding Janux Therapeutics Inc’s promising developments in their prostate cancer program. The company is expected to release mature data from their Phase 1 trials in the fourth quarter of 2025, which includes their innovative T cell engaging therapies, JANX007 and JANX008. These therapies have shown potential in the prostate cancer space, particularly with JANX007, which is being tested in earlier line metastatic castration-resistant prostate cancer (mCRPC) settings. The potential market for these treatments is significant, with a total addressable market of approximately $10 billion in the U.S. alone.
Another reason for the Buy rating is the promising preliminary data from the JANX007 trials, which show improved efficacy and durability of responses in the taxane-naive setting. The company is exploring different dosing regimens, such as a bi-weekly schedule, which could enhance safety profiles while maintaining efficacy. Additionally, Janux’s strong cash position of approximately $989 million as of September 2025 provides a solid financial foundation to support ongoing research and development efforts. These factors, combined with the potential for significant market impact, underpin Soumit Roy’s positive outlook on Janux Therapeutics Inc.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.